The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1534-6269
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines) ; volume:23 ; number:11 ; day:27 ; month:8 ; year:2021 ; pages:1-15 ; date:11.2021
Current oncology reports ; 23, Heft 11 (27.8.2021), 1-15, 11.2021
- Urheber
-
De Giglio, Andrea
Di Federico, Alessandro
Nuvola, Giacomo
Deiana, Chiara
Gelsomino, Francesco
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11912-021-01124-9
- URN
-
urn:nbn:de:101:1-2022012305445895792043
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:38 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- De Giglio, Andrea
- Di Federico, Alessandro
- Nuvola, Giacomo
- Deiana, Chiara
- Gelsomino, Francesco
- SpringerLink (Online service)
Ähnliche Objekte (12)
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Expression of PD-L1, CTLA-4, and LAG-3 in human thyroid carcinoma
MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Expression of PD-L1, CTLA-4, and LAG-3 in human thyroid carcinoma
MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Expression of PD-L1, CTLA-4, and LAG-3 in human thyroid carcinoma
MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways